Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning
Frontiers in Healthcare Technology · 2026-01-18 · 3 (1) · 31-39
DOI: 10.71465/fht613 ↗At a glance
Journal article in Frontiers in Healthcare Technology, published online on 2026-01-18. Written by James Smith and 2 co-authors. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
The advent of immune checkpoint inhibitors has revolutionized the landscape of oncological treatment, particularly for solid tumors such as melanoma and non-small cell lung cancer. However, the efficacy of these therapies remains heterogeneous, with a significant fraction of patients failing to exhibit a durable objective response. Traditional biomarkers, including PD-L1 expression levels and tumor mutational burden, lack the requisite sensitivity and specificity to accurately stratify patients in a clinical setting. This paper proposes a comprehensive multi-modal deep learning framework designed to predict the therapeutic efficacy of immune checkpoint inhibitors by integrating whole slide histopathology images, genomic sequencing data, and baseline clinical demographics. By employing a late-fusion architecture that utilizes attention mechanisms to weigh the relative importance of distinct modalities, the proposed model captures the complex non-linear interactions between the tumor microenvironment and the host immune system. Experimental results on a large-scale retrospective cohort demonstrate that this multi-modal approach significantly outperforms unimodal baselines and current standard-of-care biomarkers. The study provides a pathway toward precision immuno-oncology, highlighting the critical role of artificial intelligence in deciphering the biological heterogeneity of cancer response mechanisms.
Cite
APA
Smith, J., Anderson, R., & Miller, W. (2026). Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning. Frontiers in Healthcare Technology, 3(1), 31-39. https://doi.org/10.71465/fht613
Vancouver
Smith J, Anderson R, Miller W. Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning. Frontiers in Healthcare Technology. 2026;3(1):31-39. doi:10.71465/fht613
BibTeX
@article{Smith2026,
author = {Smith, James and Anderson, Robert and Miller, William},
title = {Predicting Efficacy of Immune Checkpoint Inhibitors in Targeted Oncology Therapy using Multi-Modal Deep Learning},
journal = {Frontiers in Healthcare Technology},
year = {2026},
volume = {3},
number = {1},
pages = {31--39},
doi = {10.71465/fht613}
}
EUVIMED